<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502021</url>
  </required_header>
  <id_info>
    <org_study_id>Flaxseed01</org_study_id>
    <nct_id>NCT00502021</nct_id>
  </id_info>
  <brief_title>Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation</brief_title>
  <official_title>Inflammatory Indicators and Arterial Stiffness in Patients With Severe Obesity. Response to Supplementation of Alpha Linolenic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary studies have shown that flaxseed powder, rich in the omega-3 alpha-linolenic
      acid,is beneficial for the general inflammation present in morbidly obese subjects by
      decreasing elevated serum markers.As omega-3 fatty acids display additional properties
      including possible amelioration of atherosclerosis,a 3-month supplementation protocol was
      devised.Arterial stiffness and intima thickness will be measured in severely obese subjects,
      in order to document possible reduction of these variables as well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population:Morbidly obese non-smoking patients of the Department of Gastroenterology,
      candidates for possible bariatric treatment Criteria for inclusion: Males and females, 18- 65
      years old, body mass index/BMI &gt; 40 kg/m2 (or &gt; 35 kg/m2 with comorbidities),
      non-hospitalized and receiving general oral diet, with elevated C-reactive protein/ CRP (&gt;
      5mg/L), and signing informed consent; Criteria for exclusion: SIRS, shock, coma or organ
      failure, fever or infectious foci, cancer with or without chemo/radiotherapy, inflammatory
      illnesses (rhematic, gastrointestinal or other), transplantation or immunologic diseases,
      trauma, surgery or hospitalization in the last 30 days, use of steroidal or non-steroidal
      anti-inflammatory or immune-modulating agents or antibiotics, and refusal to participate in
      the study; Dietetic routine: Daily flaxseed powder (Farinha de linhaca dourada) 60 g/day (232
      kcal , containing 10 g of alpha-linolenic acid/ALA) or placebo (commercial manioc flour 60
      g/day, 120 kcal)) during 12 weeks. An additional 60 subjects (30 patients, 30 controls) will
      ve managed with 30 ml/day flaxseed oil (10 g of alpha-linolenic acid/ALA) or 30 ml/day
      placebo (safflower oil).

      Methods: Clinical questionnaire,nutritional assessment(Weight, height, BMI) Biochemical
      tests: Hemoglobin (HB) , white blood cell count (WBC), total cholesterol (CHOL) and fractions
      (HDL, LDL, VLDL), triglycerides (TRIG), blood glucose (GLU), serum albumin (ALB),insulin
      (INS), leptin (LEP),C-reactive protein (CRP), serum amyloid A (SAA), complement fractions C3
      and C4, coagulation profile Atherosclerosis markers: Arterial stiffness (aorta) and intima
      thickness (common carotid artery)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in arterial stiffness/intima thickness</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in inflammatory markers and serum lipids</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Atherosclerosis</condition>
  <condition>Systemic Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplement of flaxseed powder (60 g/day)during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo powder supplement 60 g/day during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Safflower oil 30 ml/day (no ALA) during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Manioc powder (placebo) 60 g/day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cassava powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha-linolenic acid/ALA</intervention_name>
    <description>Flaxseed powder 60 g/day (10 g ALA)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Linseed powder, omega- 3 fatty acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha linolenic acid/ALA</intervention_name>
    <description>Flaxseed oil 30 ml/day (10 g ALA)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Linseed oil, omega- 3 fatty acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safflower oil 30 ml/day</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Omega 6 fatty acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  18- 65 years old

          -  Body mass index/BMI &gt; 40 kg/m2 (or &gt; 35 kg/m2 with comorbidities)

          -  Non-hospitalized and receiving general oral diet

          -  With elevated C-reactive protein/ CRP (&gt; 5mg/L); and

          -  Signing informed consent

        Exclusion Criteria:

          -  SIRS, shock, coma or organ failure,

          -  Fever or infectious foci

          -  Cancer with or without chemo/radiotherapy

          -  Inflammatory illnesses (rhematic, gastrointestinal or other), transplantation or
             immunologic diseases

          -  Trauma, surgery or hospitalization in the last 30 days

          -  Use of steroidal or non-steroidal anti-inflammatory or immune-modulating agents or
             antibiotics; and

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Faintuch, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sao Paulo University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia C Marques, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joel Faintuch</last_name>
    <phone>5511- 330697561</phone>
    <phone_ext>18</phone_ext>
    <email>jfaintuch@hcnet.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia C Marques</last_name>
    <phone>5511-30697561</phone>
    <phone_ext>18</phone_ext>
    <email>patipaticamar@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas-ICHC-9th Floor- Av. Eneias C. Aguiar 255</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C Marques, MD</last_name>
      <phone>5511-30697561</phone>
      <phone_ext>18</phone_ext>
      <email>patipaticamar@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ivan Cecconello, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Faintuch J, Horie LM, Barbeiro HV, Barbeiro DF, Soriano FG, Ishida RK, Cecconello I. Systemic inflammation in morbidly obese subjects: response to oral supplementation with alpha-linolenic acid. Obes Surg. 2007 Mar;17(3):341-7.</citation>
    <PMID>17546842</PMID>
  </reference>
  <reference>
    <citation>Faintuch J, Horie LM, Schmidt VD, Barbeiro HV, Barbeiro DF, Soriano FG, Cecconello I. Obesity, inflammation, vascular reactivity, and cardiocirculatory events. Clinics (Sao Paulo). 2007 Jun;62(3):357-8.</citation>
    <PMID>17589679</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Joel Faintuch</investigator_full_name>
    <investigator_title>Associate Professor, Department of Gastroenterology, Sao Paulo University Medical School</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>alpha linolenic acid</keyword>
  <keyword>flaxseed</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

